No Results Found
The page you requested could not be found. Try refining your search, or use the navigation above to locate the post.
FDA Review and Phase III Alert: Biocon’s Ustekinumab Biosimilar
On 16 May 2024, Biocon reported that the US’s FDA had accepted Biocon’s BLA for Bmab 1200 (bUstekinumab) for review under the 351(k) pathway. Biocon had earlier signed a settlement and license agreement with Janssen Biotech Inc. and Johnson & Johnson that allows...